Evidence map›Paper›PMID 35149037›Full record

Trial reportAmerican heart journal2022

Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial.

Mandeep S Sidhu, Karen P Alexander, Zhen Huang, Sean M O'Brien, Bernard R Chaitman, Gregg W Stone, Jonathan D Newman, William E Boden, Aldo P Maggioni, Philippe Gabriel Steg and 25 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in American heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Long-term follow-up after invasive or conservative management of stable coronary disease: the ISCHEMIA-EXTEND study.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 10 countries.

Mandeep S SidhuAlbany Medical College, Albany, NY. Electronic address: sidhum@amc.edu.
Karen P AlexanderDuke Clinical Research Institute - Duke University Medical Center, Durham, NC.
Zhen HuangDuke Clinical Research Institute - Duke University Medical Center, Durham, NC.
Sean M O'BrienDuke Clinical Research Institute - Duke University Medical Center, Durham, NC.
Bernard R ChaitmanSt Louis University School of Medicine Center for Comprehensive Cardiovascular Care, St. Louis, MO.
Gregg W StoneIcahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York, NY.
Jonathan D NewmanNYU Grossman School of Medicine, New York, NY.
William E BodenVA New England Healthcare System, Boston University School of Medicine, Boston, MA.
Aldo P MaggioniANMCO Research Center, Florence, Italy.
Philippe Gabriel StegUniversité de Paris, Assistance Publique-Hôpitaux de Paris, INSERM-1148, Paris, France.
Thomas B FergusonBrody School of Medicine, East Carolina University, Greenville, NC, USA.
Marcin DemkowDept of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland.
Jesus PeteiroCHUAC, Universidad de A Coruña, CIBER-CV, A Coruña, Spain.
Gurpreet S WanderDayanand Medical College & Hospital, Ludhiana, Punjab, India.
Denis C PhaneufHôpital Pierre-Le Gardeur, Quebec, Terrebonne, Canada.
Mark A De BelderBarts Health NHS Trust, London, United Kingdom.
Rolf DoerrPraxisklinik Herz und Gefaesse, Dresden, Germany.
Erick Alexanderson-RosasInstituto Nacional de Cardiología "Ignacio Chávez", Mexico City, Mexico.
Carisi A PolanczykFederal University of Rio Grande do Sul, Hospital Clínicas de Porto Alegre, Porto Alegre, Brazil.
Peter A HenriksenEdinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Dwayne S G ConwayNorthern General Hospital, Sheffield, United Kingdom.
Vicente MiroHospital universitario y politecnico La Fe, Valencia, Spain.
Tali SharirAssuta Medical Center and Ben Gurion University of the Negev, Tel Aviv, Israel.
Renato D LopesDuke Clinical Research Institute - Duke University Medical Center, Durham, NC.
James K MinCleerly, Inc. New York, NY.
Daniel S BermanCedars-Sinai Medical Center, Los Angeles, CA.
Frank W RockholdDuke Clinical Research Institute - Duke University Medical Center, Durham, NC.
Stephen BalterColumbia University, New York, NY.
David BorregoRadiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Yves D RosenbergNational Institute of Health- NHLBI, Bethesda, MD.
Sripal BangaloreNYU Grossman School of Medicine, New York, NY.
Harmony R ReynoldsNYU Grossman School of Medicine, New York, NY.
Judith S HochmanNYU Grossman School of Medicine, New York, NY.
David J MaronDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
ISCHEMIA Research Group
New York University · USClinical Research Institute · USDuke Medical Center · USAlbany Medical Center Hospital · USAssistance Publique – Hôpitaux de Paris · FRAssociazione Nazionale Medici Cardiologi Ospedalieri · ITBarts Health NHS Trust · GBBoston University · USCardiovascular Research Foundation · USCedars-Sinai Medical Center · USColumbia University · USComplexo Hospitalario Universitario A Coruña · ESComprehensive Cardiovascular · USCorona (Poland) · PLDayanand Medical College & Hospital · INEast Carolina University · USEdinburgh Royal Infirmary · GBHospital de Clínicas de Porto Alegre · BRInstituto Nacional de Cardiología · MXNational Cancer Institute · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
Molecular predictors of resistance and vulnerability to cardiovascular events in stable ischemic heart diseaseR56HL155528 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEWMAN, JONATHAN D, RUGGLES, KELLY VALENTINE · 2021 to 2021
$492k
NCATS NIH HHS UL1 TR001445NCATS NIH HHS UL1 TR002243NHLBI NIH HHS R56 HL155528NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

backgroundThe International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial demonstrated no overall difference in the composite primary endpoint and the secondary endpoints of cardiovascular (CV) death/myocardial infarction or all-cause mortality between an initial invasive or conservative strategy among participants with chronic coronary disease and moderate or severe myocardial ischemia. Detailed cause-specific death analyses have not been reported.

methodsWe compared overall and cause-specific death rates by treatment group using Cox models with adjustment for pre-specified baseline covariates. Cause of death was adjudicated by an independent Clinical Events Committee as CV, non-CV, and undetermined. We evaluated the association of risk factors and treatment strategy with cause of death.

resultsFour-year cumulative incidence rates for CV death were similar between invasive and conservative strategies (2.6% vs 3.0%; hazard ratio [HR] 0.98; 95% CI [0.70-1.38]), but non-CV death rates were higher in the invasive strategy (3.3% vs 2.1%; HR 1.45 [1.00-2.09]). Overall, 13% of deaths were attributed to undetermined causes (38/289). Fewer undetermined deaths (0.6% vs 1.3%; HR 0.48 [0.24-0.95]) and more malignancy deaths (2.0% vs 0.8%; HR 2.11 [1.23-3.60]) occurred in the invasive strategy than in the conservative strategy.

conclusionsIn International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, all-cause and CV death rates were similar between treatment strategies. The observation of fewer undetermined deaths and more malignancy deaths in the invasive strategy remains unexplained. These findings should be interpreted with caution in the context of prior studies and the overall trial results.

Indexed as

Coronary Artery DiseaseMyocardial InfarctionMyocardial IschemiaHumansIschemiaRisk Factors

Identifiers

PMID35149037
PMCPMC9310436
OpenAlexW4210843740

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.